STOCK TITAN

Longitude investors disclose 12.5% Veradermics (MANE) stake after IPO

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D

Rhea-AI Filing Summary

Veradermics, Incorporated disclosed that venture funds affiliated with Longitude Capital and managing members Patrick G. Enright and Juliet Tammenoms Bakker have filed a Schedule 13D reporting a significant stake in its common stock. The Reporting Persons beneficially own 4,653,873 shares of common stock, representing 12.5% of the outstanding shares based on 37,339,464 shares outstanding as of February 5, 2026.

Longitude Venture Partners V, L.P. holds 2,600,399 shares, and Longitude 103.8 East, L.P. holds 2,053,474 shares, with voting and dispositive power shared through their general partners. These positions arose from investments in Veradermics’ Series B and Series C preferred stock and additional common shares purchased at $17.00 per share in the initial public offering. The investors state they hold the shares for general investment purposes, may increase or decrease their holdings over time, and are subject to a 180‑day lock-up following the IPO underwriting agreement.

Positive

  • None.

Negative

  • None.





If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D




Comment for Type of Reporting Person:
All shares are held of record by LVPV (as defined in Item 2(a) below). LCPV (as defined in Item 2(a) below) is the general partner of LVPV and may be deemed to have voting and dispositive power with respect to these securities. Patrick G. Enright, a member of the Issuer's board of directors, and Juliet Tammenoms Bakker are the managing members of LCPV and may each be deemed to share voting and dispositive power with respect to these securities. Based on 37,339,464 shares of Common Stock outstanding as of February 5, 2026, as reported by the Issuer (as defined in Item 1(a) below) in its prospectus filed with the United States Securities and Exchange Commission (the Commission) on February 4, 2026 (the Prospectus), including the full exercise of the underwriters' option to purchase 2,261,647 additional shares of Common Stock.


SCHEDULE 13D




Comment for Type of Reporting Person:
All shares are held of record by LVPV. LCPV is the general partner of LVPV and may be deemed to have voting and dispositive power with respect to these securities. Patrick G. Enright, a member of the Issuer's board of directors, and Juliet Tammenoms Bakker are the managing members of LCPV and may each be deemed to share voting and dispositive power with respect to these securities. Based on 37,339,464 shares of Common Stock outstanding as of February 5, 2026, as reported by the Issuer in the Prospectus, including the full exercise of the underwriters' option to purchase 2,261,647 additional shares of Common Stock.


SCHEDULE 13D




Comment for Type of Reporting Person:
All shares are held of record by L103 (as defined in Item 2(a) below). L103P (as defined in Item 2(a) below) is the general partner of L103 and may be deemed to have voting and dispositive power with respect to these securities. Patrick G. Enright, a member of the Issuer's board of directors, and Juliet Tammenoms Bakker are the managing members of L103P and may each be deemed to share voting and dispositive power with respect to these securities. Based on 37,339,464 shares of Common Stock outstanding as of February 5, 2026, as reported by the Issuer in the Prospectus, including the full exercise of the underwriters' option to purchase 2,261,647 additional shares of Common Stock.


SCHEDULE 13D




Comment for Type of Reporting Person:
All shares are held of record by L103. L103P is the general partner of L103 and may be deemed to have voting and dispositive power with respect to these securities. Patrick G. Enright, a member of the Issuer's board of directors, and Juliet Tammenoms Bakker are the managing members of L103P and may each be deemed to share voting and dispositive power with respect to these securities. Based on 37,339,464 shares of Common Stock outstanding as of February 5, 2026, as reported by the Issuer in the Prospectus, including the full exercise of the underwriters' option to purchase 2,261,647 additional shares of Common Stock.


SCHEDULE 13D




Comment for Type of Reporting Person:
Consists of (i) 2,600,399 shares of Common Stock held of record by LVPV, and (ii) 2,053,474 shares of Common Stock held of record by L103. LCPV is the general partner of LVPV and may be deemed to have voting and dispositive power with respect to the shares held of record by LVPV. L103P is the general partner of L103 and may be deemed to have voting and dispositive power with respect to the shares held by L103. Patrick G. Enright, a member of the Issuer's board of directors, and Juliet Tammenoms Bakker are the managing members of each of LCPV and L103 and may each be deemed to share voting and dispositive power with respect to the shares held by LVPV and L103. Based on 37,339,464 shares of Common Stock outstanding as of February 5, 2026, as reported by the Issuer in the Prospectus, including the full exercise of the underwriters' option to purchase 2,261,647 additional shares of Common Stock.


SCHEDULE 13D




Comment for Type of Reporting Person:
Consists of (i) 2,600,399 shares of Common Stock held of record by LVPV, and (ii) 2,053,474 shares of Common Stock held of record by L103. LCPV is the general partner of LVPV and may be deemed to have voting and dispositive power with respect to the shares held of record by LVPV. L103P is the general partner of L103 and may be deemed to have voting and dispositive power with respect to the shares held by L103. Patrick G. Enright, a member of the Issuer's board of directors, and Juliet Tammenoms Bakker are the managing members of each of LCPV and L103P and may each be deemed to share voting and dispositive power with respect to the shares held by LVPV and L103. Based on 37,339,464 shares of Common Stock outstanding as of February 5, 2026, as reported by the Issuer in the Prospectus, including the full exercise of the underwriters' option to purchase 2,261,647 additional shares of Common Stock.


SCHEDULE 13D


Longitude Capital Partners V, LLC
Signature:/s/ Cristiana Blauth Oliveira
Name/Title:Cristiana Blauth Oliveira, Authorized Signatory
Date:02/12/2026
Longitude Venture Partners V, L.P.
Signature:By Longitude Capital Partners V, LLC, General Partner, /s/ Cristiana Blauth Oliveira
Name/Title:Cristiana Blauth Oliveira, Authorized Signatory
Date:02/12/2026
Longitude 103.8 East Partners, LLC
Signature:/s/ Cristiana Blauth Oliveira
Name/Title:Cristiana Blauth Oliveira, Authorized Signatory
Date:02/12/2026
Longitude 103.8 East, L.P.
Signature:By Longitude 103.8 East Partners, LLC, General Partner, /s/ Cristiana Blauth Oliveira
Name/Title:Cristiana Blauth Oliveira, Authorized Signatory
Date:02/12/2026
Patrick G. Enright
Signature:/s/ Cristiana Blauth Oliveira
Name/Title:Cristiana Blauth Oliveira, as attorney-in-fact for Patrick G. Enright
Date:02/12/2026
Juliet Tammenoms Bakker
Signature:/s/ Cristiana Blauth Oliveira
Name/Title:Cristiana Blauth Oliveira, as attorney-in-fact for Juliet Tammenoms Bakker
Date:02/12/2026

FAQ

What ownership stake does Longitude Capital report in Veradermics (MANE)?

Longitude-related investors report beneficial ownership of 4,653,873 Veradermics shares, equal to 12.5% of the company’s common stock based on 37,339,464 shares outstanding as of February 5, 2026, following the company’s initial public offering and related share conversions.

How many Veradermics (MANE) shares are held by each main Longitude fund?

Longitude Venture Partners V, L.P. holds 2,600,399 Veradermics common shares, while Longitude 103.8 East, L.P. holds 2,053,474 shares. Voting and dispositive power over these holdings is shared through their respective general partners, managed by Patrick G. Enright and Juliet Tammenoms Bakker.

How did Longitude Capital build its Veradermics (MANE) position?

Longitude funds bought Veradermics Series B preferred stock in November 2024 for about $15.0 million and Series C preferred stock in October 2025 for about $30.0 million. These preferred shares later converted into common shares upon the company’s initial public offering.

What Veradermics (MANE) IPO purchases did Longitude entities make?

In the initial public offering, Longitude Venture Partners V, L.P. bought 192,647 Veradermics common shares at $17.00 per share, and Longitude 103.8 East, L.P. bought 882,353 shares at the same price, adding to their existing positions from preferred stock investments.

Are Longitude Capital and its principals locked up from selling Veradermics (MANE) shares?

Yes. Each Reporting Person entered lock-up agreements in connection with the offering. They agreed, subject to certain exceptions, not to sell, transfer or otherwise convey Veradermics securities they hold for 180 days following the date of the IPO underwriting agreement.

What is Longitude Capital’s stated purpose for holding Veradermics (MANE) shares?

The investors state they hold Veradermics securities for general investment purposes. They may buy more shares, sell shares, or adjust their position over time based on market conditions, Veradermics’ prospects, other opportunities, tax considerations and similar factors they consider relevant.

Do the Longitude Reporting Persons form a group in Veradermics (MANE) stock?

The Schedule 13D is filed jointly by multiple Longitude entities and individuals, but they expressly disclaim status as a “group” for purposes of beneficial ownership rules, other than where a person directly holds securities reported in the statement.
VERADERMICS INC

NYSE:MANE

MANE Rankings

MANE Latest News

MANE Latest SEC Filings

MANE Stock Data

1.52B
15.08M